CD20 Antibody – Optimizing CAR-T Therapy Strategies for B-Cell Non-Hodgkin Lymphoma
CD20 Antibody – Optimizing CAR-T Therapy Strategies for B-Cell Non-Hodgkin Lymphoma
Concept
CD20 is a B-cell–restricted tetraspan membrane protein (35 kDa) encoded by the MS4A1 gene. It is stably expressed on pre-B and mature B lymphocytes but absent on hematopoietic stem cells, pro-B cells, and plasma cells. This lineage-specific expression makes CD20 an ideal target for treating B-cell malignancies and optimizing CAR-T immunotherapy.
Research Frontier
CD20 has emerged as a key rescue target to overcome CD19 antigen escape in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Current innovation focuses on CD20-specific CAR-T design, dual-target (CD19/CD20) combinatorial strategies, epitope-optimized antibodies, and companion diagnostic tools to improve persistence, safety, and clinical response rates.
Research Significance
CD20 targeting addresses critical limitations of CD19 CAR-T:
- Resolves antigen escape (downregulation/loss of CD19)
- Expands therapeutic options for CD19-refractory patients
- Maintains high tumor coverage while sparing plasma cells
- Supports durable immune synapse formation due to stable membrane expression
- Enables personalized sequential or combination CAR-T regimens
Core Mechanisms and Strategic Applications
Unique Biological Features of CD20
- Strict B-cell lineage restriction
- Stable surface expression (low internalization/shedding)
- Non-essential for normal B-cell survival, enabling safe depletion
- Expression profile complementary to CD19 during B-cell development
How CD20 Fixes CD19 CAR-T Limitations
- CD19 failure affects ~20% of patients via antigen loss
- CD20 and CD19 are regulated independently, preventing dual escape
- CD20 CAR-T serves as a reliable salvage therapy
- Combined CD19/CD20 targeting reduces relapse risk
Challenges and Opportunities
- Optimize CAR affinity/specificity
- Balance efficacy and B-cell depletion safety
- Address heterogeneous CD20 expression
- Enable sequential, combined, or epitope-specific targeting
Clinical Positioning
- Salvage therapy after CD19 CAR-T failure
- Combination with anti-CD20 monoclonal antibodies
- Patient stratification and companion diagnostics
- Precision therapy based on CD20 expression status
Future Directions
- Next-generation CAR designs with enhanced signaling
- Combination with checkpoint inhibitors
- Predictive biomarkers for response
- Multi-target and universal CAR-T platforms
Product Empowerment
ANT BIO PTE. LTD. provides the S-RMab® CD20 Recombinant Rabbit Monoclonal Antibody (SDT-R133, Cat. No. S0B2158) under its Starter product line. This high-performance reagent enables specific, sensitive, and consistent detection of CD20 in FFPE tissues and cellular samples.
It supports lymphoma diagnosis, CAR-T target validation, immunotherapy monitoring, and B-cell subset analysis—essential for advancing CD20-directed precision medicine.
Core Product Advantages
表格
|
Core Product Advantages |
|
High Specificity & Precise Membrane Staining: Specifically recognizes human CD20; clear, sharp membrane localization in FFPE sections with clean background. |
|
Superior Stability & Batch-to-Batch Consistency: Rigorous quality control ensures minimal inter-batch variation and reliable performance for clinical diagnostics. |
|
Broad Research & Diagnostic Compatibility: Validated for IHC and compatible with immunophenotyping, CAR-T target validation, and companion diagnostic development. |
Key Application Scenarios
表格
|
Key Application Scenarios |
|
B-Cell Lymphoma Diagnosis & Subtyping: Identification of diffuse large B-cell lymphoma, follicular lymphoma, CLL, and other B-NHL subtypes. |
|
B-Cell Quantification & Immunophenotyping: Detection and counting of normal and malignant B-cell populations. |
|
CD20-Targeted Therapy Monitoring: Companion diagnostic for anti-CD20 antibodies and CAR-T efficacy assessment. |
|
Autoimmune Disease Research: Analysis of B-cell infiltration in rheumatoid arthritis, multiple sclerosis, and related disorders. |
Brand Mission
ANT BIO PTE. LTD. is a leading provider of life science reagents, offering antibodies, recombinant proteins, assay kits, and general laboratory reagents. We operate three specialized sub-brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions for oncology, immunology, CAR-T research, and precision medicine. We are committed to supplying high-quality, consistent, and innovative tools to advance targeted immunotherapy and improve outcomes for B-cell malignancy patients.
Related Product List
表格
|
Product Name |
Catalog No. |
Applications |
|
CD20 Recombinant Rabbit Monoclonal Antibody (SDT-R133) |
S0B2158 |
IHC, B-cell detection, lymphoma diagnosis |
|
CD19/CD20 Dual Marker Antibody Panel |
Starter series |
CAR-T target screening and validation |
|
IHC Detection Kits & Antigen Retrieval Buffers |
Absin series |
Standardized CD20 staining |
|
Recombinant CD20 Protein |
UA-series |
Antigen validation and CAR binding assays |
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
